QuidelOrtho Reports Fourth Quarter and Full-Year Financial Results
QuidelOrtho Corporation, a prominent player in the innovative in vitro diagnostics sector, has made headlines with its financial results for the fourth quarter and full-year performance. The company reported significant growth and expansion in key segments, showcasing resilience in a challenging market landscape.
In the latest fiscal year, QuidelOrtho experienced 6% growth in laboratory services and 9% in its TRIAGE™ product line, alongside a notable expansion of 240 basis points in adjusted EBITDA margins. According to CEO Brian J. Blaser, the company has successfully transitioned from the volatility caused by the COVID-19 pandemic to a more stable and diversified diagnostics business.
Fourth Quarter 2025 Results Overview
For the fourth quarter of 2025, QuidelOrtho reported:
- Total revenue of $724 million, marking a consistent performance compared to the prior year.
- Non-respiratory revenue included earnings of $600 million, showcasing a 7% growth in constant currency when excluding the Donor Screening segment.
- Tracking the respiratory revenue, it stood at $123 million but showed a 14% decline attributed mainly to reduced COVID-19 testing demands.
- GAAP operating cash flow was logged at $132 million; however, free cash flow came in at $87 million.
This solid performance occurred despite a GAAP net loss of $131 million and adjusted EBITDA of $153 million. The adjusted diluted earnings per share (EPS) was reported at $0.46, reflecting the underlying strength of the business.
Full-Year 2025 Performance Details
Examining the full-year results, the figures were equally compelling:
- Total revenue was $2.73 billion, aligning with internal guidance.
- Excluding Donor Screening, non-respiratory revenue grew by 5% in constant currency to reach $2.33 billion.
- Revenue from respiratory products totaled $402 million, which still marked a 20% decline year-over-year.
Despite the overall net loss reported at $1.13 billion and an operating loss of $0.92 billion, adjustments related to non-cash goodwill impairment of $701 million heavily influenced these results. The underlying operations yielded an adjusted EBITDA of $597 million.
Financial Guidance for 2026
Based on the current business dynamics, QuidelOrtho provided guidance for fiscal year 2026, projecting:
- Total revenues expected to range between $2.70 billion and $2.90 billion.
- Adjusted EBITDA forecasted to be between $630 million and $670 million.
- Adjusted diluted EPS is anticipated in the range of $2.00 to $2.42.
The company also expects free cash flow to improve significantly, potentially reaching between $120 million and $160 million.
Leadership Transition
QuidelOrtho also announced the upcoming retirement of Chief Financial Officer Joseph M. Busky, effective June 30, 2026. His contributions have been vital in the financial structuring and cost-savings initiatives, leading to a whopping $140 million in savings by the end of 2025. Post-retirement, he will assist in the transitional phase, ensuring a seamless handover of responsibilities.
Conclusion
QuidelOrtho's strategic positioning and focused management have prepared the company for future challenges and opportunities in the healthcare diagnostics sector. Their commitment to driving innovation in diagnostics highlights their resilience and adaptability in a rapidly changing industry.
Frequently Asked Questions
1. What were QuidelOrtho's total revenues in the fourth quarter of 2025?
Total revenue for the fourth quarter of 2025 was reported at $724 million.
2. How did QuidelOrtho perform in non-respiratory revenue?
Non-respiratory revenue included $600 million, which reflects a 7% growth in constant currency.
3. What is the expected EPS for QuidelOrtho in FY 2026?
The adjusted diluted EPS for FY 2026 is anticipated to be in the range of $2.00 to $2.42.
4. What cost-saving initiatives led to the financial improvements reported?
Cost-savings measures implemented by the management resulted in a total of $140 million in savings by 2025.
5. Who will take over after the retirement of Joseph M. Busky?
A successor for the Chief Financial Officer position is currently being sought by QuidelOrtho, and Joseph M. Busky will assist in the transition.
